Myriad Genetics (MYGN) Reports In-Line Q3 EPS
Tweet
Share
E-mail
Get Alerts MYGN Hot Sheet
Price: $4.01 +3.08%
Revenue Growth %: -7.0%
Financial Fact:
Companion diagnostic services: 12.4M
Today's EPS Names:
ALZN, ASPU, OCCI, More
Revenue Growth %: -7.0%
Financial Fact:
Companion diagnostic services: 12.4M
Today's EPS Names:
ALZN, ASPU, OCCI, More
Join SI Premium – FREE
Myriad Genetics (NASDAQ: MYGN) reported Q3 EPS of ($0.02), in-line with the analyst estimate of ($0.02). Revenue for the quarter came in at $167.3 million versus the consensus estimate of $165.04 million.
For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- CMS targets 15% Medicare lab fee cuts, putting DGX and LH revenue at risk
- Kotak Starts INDO-MIM Ltd (INDOMIM:IN) at Reduce (3)
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
